

**HEALTH TECHNOLOGY APPRAISAL: NICE Health Technology  
Appraisal - Appraisal Consultation Document  
Imatinib for the treatment of unresectable and/or metastatic  
gastrointestinal stromal tumours**

**TO: NICE**

**FROM: NHS Quality Improvement  
Scotland  
20 July 2010**

To the best of my knowledge I believe all the relevant evidence on the subject has been taken into account.

The summaries of Clinical and Cost effectiveness are reasonable interpretations of the evidence, the provisional recommendations are sound and a suitable basis for guidance to the NHS.

I do not believe there are aspects of the recommendations that need particular consideration to avoid unlawful discrimination.

